【海普瑞：依诺肝素钠注射液获阿根廷批件】金十数据2月26日讯，海普瑞公告，公司全资孙公司天道医药收到阿根廷国家药品、食品和医疗器械管理局批准，依诺肝素钠注射液可在阿根廷市场销售。此批准进一步提升了海普瑞依诺肝素钠制剂的全球市场占有率，标志着公司在国际化布局中取得重要成果。截至目前，海普瑞依诺肝素钠制剂已在全球40多个国家及地区获批上市，包括中国、美国、欧盟等主要市场。海普瑞计划继续拓展全球市场，加快销售渠道建设，为进一步加强海外市场发展奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.